Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Gene Expressed in Prostate Cancer and Methods of Use

Posted Feb 16 2011 7:00pm

Description of Invention:
Prostate cancer is the second leading cause of cancer-related deaths among males in the United States. There are approximately two hundred and fifteen thousand (215,000) newly diagnosed cases of prostate cancer and thirty thousand (30,000) prostate cancer-related deaths each year, underscoring the importance of addressing this deadly disease. Although there are diagnostic test in place for identifying the potential for developing prostate cancer, even the most widely accepted diagnostic for detecting cancer (prostate-specific antigen or PSA) is capable of producing a false negative result. Furthermore, current treatments are invasive and may produce deleterious side-effects. Therefore, there is a clear need to identify and develop new and effective diagnostics and treatments for prostate cancer.

This technology concerns the identification of a novel protein that is specifically expressed on prostate tissue: Novel Gene Expressed in Prostate (NGEP). Because of its selective expression on prostate tissue, NGEP represents a potential target in the fight against prostate cancer. Monoclonal antibodies that specifically recognize NGEP have been developed in conjunction with the identification of the protein. These antibodies can be used as both diagnostic agents and therapeutic agents.

Applications:
  • Antibodies to NGEP can be used as diagnostic agents to identify metastatic prostate tissue, either alone or in combination with other diagnostic antibodies
  • Antibodies to NGEP can also be used therapeutically to specifically target cytotoxic agents to prostate cancer cells or to induce antibody-dependent cell-mediated cytotoxicity (ADCC)
  • Antibodies to NGEP can be used as research reagents for identifying prostate tissue, including cancerous tissue


Advantages:
  • The selective expression of NGEP allows the specific detection and recognition of prostate tissue, which is useful in both diagnostic and therapeutic applications
  • Combining the detection of NGEP with other prostate cancer diagnostic agents may reduce the incidence of a false negative diagnosis
  • The use of NGEP antibodies in targeted therapy can decrease the non-specific killing of non-cancerous cells, thereby decreasing side-effects associated with current prostate cancer therapies


Development Status:
Preclinical stage of development

Inventors:
Ira H Pastan (NCI)


Patent Status:
HHS, Reference No. E-005-2002/0
US, , Patent No. 7,816,087, Issued 19 Oct 2010
US, , Patent No. 7,897,335, Issued 01 Mar 2011
EP, Application No. 02795643.2 filed 01 Jun 2004


Relevant Publication:
  1. S Das et al. Topology of NGEP, a prostate-specific cell:cell junction protein widely expressed in many cancers of different grade level. Cancer Res. 2008 Aug 1;68(15):6306-6312. [ PubMed: 18676855 ]
  2. S Das et al. NGEP, a prostate-specific plasma membrane protein that promotes the association of LNCaP cells. Cancer Res. 2007 Feb 15;67(4):1594-1601. [ PubMed: 17308099 ]
  3. TK Bera et al. NGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostate. Proc Natl Acad Sci USA. 2004 Mar 2;101(9):3059-3064. [ PubMed: 14981236 ]


Licensing Status:
Available for licensing


Portfolios:
Cancer
Cancer - Diagnostics
Cancer - Therapeutics



For Licensing Information Please Contact:
David Lambertson Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: lambertsond@mail.nih.gov
Phone: 301-435-4632
Fax: 301-402-0220


Ref No: 649

Updated: 02/2011

Post a comment
Write a comment:

Related Searches